New Phase 2 Data Offers Hope for Retinitis Pigmentosa Patients
According to a report by Endpoints News, biotechnology company Aldeyra Therapeutics has announced top-line results from a small open-label study evaluating its investigational drug candidate, ADX-2191, for the treatment of retinitis pigmentosa (RP). Because retinitis pigmentosa currently has no approved treatment options, any advancement in clinical research is closely watched by the inherited retinal disease (IRD) community as patients and families search for potential therapies to preserve vision.
Study Findings and Safety Profile
The Phase 2 clinical trial evaluated eight patients with retinitis pigmentosa who had misfolding mutations of rhodopsin, a protein critical for visual function. According to the source, these specific mutations are present in approximately one-third of the estimated 1 million RP cases worldwide. Preclinical evidence indicates that methotrexate—the active ingredient formulated in ADX-2191—may help facilitate the clearance of mutated rhodopsin.
In the study, four patients received monthly intravitreal injections of ADX-2191, while the other four received injections twice a month for three months. According to Endpoints News, the trial met its primary goal of safety, with no safety concerns reported and injection site pain noted as mild or moderate. Furthermore, patients demonstrated statistically significant improvements in retinal function and visual acuity compared to baseline measurements heading into the study.
Next Steps for Regulatory Discussion
Following the readout of these Phase 2 results, Aldeyra reported that it intends to discuss a potentially pivotal Phase 2/3 clinical trial with regulatory authorities. ADX-2191 previously received orphan drug designation from the FDA for retinitis pigmentosa in August 2021.
As development continues, the IRD community awaits further updates regarding trial designs and regulatory discussions to see how these findings will shape future clinical pathways for patients affected by rhodopsin-related retinitis pigmentosa.